Key Points
- COO Robert Ainscow sold 22,500 shares on April 16 at an average price of $5.21 for $117,225 to cover tax withholding from vested equity, leaving him with 1,490,317 shares (a 1.49% reduction).
- Q1 results showed a notable miss: the company reported EPS of ($0.84) vs. a ($0.14) consensus (a $0.70 miss) despite reporting $33.32 million in revenue vs. $2.03 million expected, and it has very large negative margins and negative ROE.
- Mixed analyst and market view: market cap ~$676M, 50-day/200-day averages $5.06/$6.73 and 52-week range $3.92–$14.49; two Buy and one Sell ratings produce a consensus "Hold" with a $13 price target.
ASP Isotopes Inc. (NASDAQ:ASPI - Get Free Report) Director Duncan Moore sold 11,642 shares of the stock in a transaction that occurred on Thursday, April 16th. The stock was sold at an average price of $5.21, for a total value of $60,654.82. Following the completion of the transaction, the director directly owned 1,044,928 shares of the company's stock, valued at $5,444,074.88. This trade represents a 1.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
ASP Isotopes Stock Performance
Shares of ASPI stock opened at $5.37 on Friday. The firm has a market capitalization of $676.08 million, a price-to-earnings ratio of -2.51 and a beta of 3.59. The company has a debt-to-equity ratio of 1.04, a current ratio of 6.14 and a quick ratio of 6.10. ASP Isotopes Inc. has a 12-month low of $3.92 and a 12-month high of $14.49. The business has a 50 day simple moving average of $5.06 and a 200 day simple moving average of $6.73.
ASP Isotopes (NASDAQ:ASPI - Get Free Report) last released its earnings results on Friday, April 10th. The company reported ($0.84) earnings per share for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.70). The firm had revenue of $33.32 million during the quarter, compared to analyst estimates of $2.03 million. ASP Isotopes had a negative return on equity of 307.82% and a negative net margin of 734.14%. On average, equities research analysts anticipate that ASP Isotopes Inc. will post -0.24 EPS for the current year.
Wall Street Analysts Forecast Growth
A number of research firms have weighed in on ASPI. Weiss Ratings restated a "sell (d-)" rating on shares of ASP Isotopes in a research report on Friday, March 27th. Canaccord Genuity Group reiterated a "buy" rating and set a $11.00 price objective on shares of ASP Isotopes in a research report on Tuesday. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, ASP Isotopes presently has a consensus rating of "Hold" and an average price target of $13.00.
View Our Latest Report on ASPI
Institutional Investors Weigh In On ASP Isotopes
A number of institutional investors and hedge funds have recently modified their holdings of ASPI. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of ASP Isotopes by 9.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,613 shares of the company's stock valued at $148,000 after acquiring an additional 2,709 shares during the last quarter. Rhumbline Advisers lifted its holdings in shares of ASP Isotopes by 20.9% in the second quarter. Rhumbline Advisers now owns 78,994 shares of the company's stock valued at $581,000 after purchasing an additional 13,668 shares in the last quarter. XTX Topco Ltd purchased a new stake in shares of ASP Isotopes in the second quarter valued at $178,000. New York State Common Retirement Fund lifted its holdings in shares of ASP Isotopes by 418.2% in the second quarter. New York State Common Retirement Fund now owns 17,100 shares of the company's stock valued at $126,000 after purchasing an additional 13,800 shares in the last quarter. Finally, Invesco Ltd. lifted its holdings in shares of ASP Isotopes by 2,205.0% in the second quarter. Invesco Ltd. now owns 471,219 shares of the company's stock valued at $3,468,000 after purchasing an additional 450,776 shares in the last quarter. Institutional investors and hedge funds own 16.80% of the company's stock.
ASP Isotopes Company Profile
(
Get Free Report)
ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
